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AbstrAct
Background: Tumor microenvironment including fibrosis has a pivotal 
role in cancer growth and distant metastasis. Fibrosis is a known risk factor for 
carcinogenesis, but its biological role in disease invasion and metastasis in colorectal 
cancer (CRC) remains unclear. In particular, there is no report on how fibrosis of 
metastatic lymph nodes (MLNs) in CRC contributes to prognosis. 
Methods: We reviewed 94 colorectal adenocarcinoma patients with MLNs who 
underwent colectomy. Both the primary tumors and MLNs were analyzed for alpha-
smooth muscle actin (α-SMA) expression and collagen deposition.
Results: Higher α-SMA expression and collagen deposition in MLNs were 
associated with significantly shorter relapse-free survival and overall survival in CRC 
patients. α-SMA expression in MLNs (HR, 1.53; p = 0.034) was independent predictive 
factor of overall survival in multivariate Cox proportional hazards regression analysis 
of clinicopathological factors. In the Stage III patient subgroup, α-SMA expression 
in MLNs was a strong prognostic marker (HR, 3.01; p = 0.006). On the other hand, 
higher α-SMA expression and collagen deposition in primary tumors were associated 
with short overall survival, but they were not significant factors in multivariate 
Cox regression analyses. In MLNs, the podoplanin signals co-localized with α-SMA 
expression and were confirmed by the dual immunofluorescence staining, implying 
that the MLN stromal cells were fibroblastic reticular cells.
Conclusion: Both high collagen deposition and high α-SMA expression in MLNs 
predicted poor prognosis in CRC.
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IntroductIon
Colorectal cancer (CRC) is the third most common 
malignancy worldwide [1]. Advanced CRC metastasizes to 
many organs such as the lymph nodes (LNs), peritoneum, 
lungs, and the liver. Metastasis is implicated in 90% of all 
CRC-related deaths. Although advances in chemotherapy 
and targeted drug therapies have ensured a prolonged 
survival in CRC patients, the 5-year survival rate of 
patients with Stage III disease and LN metastasis is from 
55% to 73% for colon cancer and from 45% to 69% for 
rectal cancer, while that of patients with Stage IV disease 
and distant metastasis is less than 20% [2, 3].
LNs are immune organs that respond to peripheral 
infections through the T cell-dependent paracortical 
areas. Antigen-presenting dendritic cells within the T 
cell-dependent paracortical areas then prime the naive T 
lymphocytes. Then, through the B cells-containing cortical 
germinal follicles, the naive B lymphocytes produce 
antibodies in response to the antigen [4]. LN metastasis 
occurs when cancer cells detach from the primary 
tumor (PT), enter the lymphatics, and are subsequently 
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transported to regional LNs. LN metastasis is an invaluable 
prognostic factor in almost all cancer types. Mesenteric 
LNs are the major metastatic sites for CRC, and metastatic 
LN (MLN) number and position are used in cancer 
staging. Furthermore, metastasis of LNs prognosticates 
survival rate in CRC [5–7]. Chronic inflammation caused 
by cancer cells stimulates surrounding cells including 
fibroblasts, and activated fibroblasts with alpha-smooth 
muscle actin (α-SMA) expression produce extracellular 
matrix including collagen, finally causing tissue fibrosis. 
Fibroblasts populate stromal tissue in the 
tumor microenvironment, and are key mediators of 
fibrosis. Organ fibrosis is a risk factor for carcinogenesis 
in the cirrhotic liver, lungs, kidneys, and skin [8–
11]. Fibroblasts in cancer tissues, known as cancer-
associated fibroblasts (CAFs), cause tissue remodeling 
and reconstitution to promote invasion and metastasis 
via extracellular matrix, growth factors, and protease 
production [12]. This gamut of molecular events is termed 
stromal reaction (SR), but its role in tumor progression and 
invasiveness is still controversial. Several clinical studies 
have reported that a strong SR in CRC is related to poor 
prognosis [13–15]. However, evidence exists to suggest a 
positive correlation between SR and better prognosis [16].
The SR of MLNs has not received adequate 
attention, with only a few reports, pertaining to lung 
cancer, having been published [17, 18]. In particular, there 
was no conclusive report on how the SR status of MLNs 
in CRC contributes to prognosis. Our aim was to elucidate 
the clinical impact of fibrosis of PTs and MLNs in CRC.
rEsuLts
The median age of the patients was 66 (interquartile 
range, 60 to 72) years, and the group consisted largely 
of males, 59 (62.8%). The median follow-up time for all 
patients was 59.9 (interquartile range, 38.9 to 72.3) months. 
Among the patients, 32 deaths and 23 relapse occurred. 
The representative images of the PT (Figure 1A) 
and the MLN (Figure 1B) based on the evaluated PT and 
MLN sections by hematoxylin and eosin (H&E), depict 
that both tissue types showed α-SMA expression and 
collagen deposition. Furthermore, in order to characterize 
the fibroblast, we performed immunohistochemistry (IHC) 
staining of fibronectin, fibroblast activation protein (FAP), 
and CD31 (Supplementary Figure 1).
We compared the diameters of 147 MLNs in various 
patients and the staining rate of α-SMA or collagen, and 
showed that there was no correlation between the diameter 
and the degree of fibrosis in MLN; Pearson’s correlation 
coefficients were 0.171 and 0.119, respectively. 
In a subset of 41 patients with multiple MLNs, 
a strong positive correlation was found between the 
α-SMA expression rate of the largest-diameter MLN and 
the average α-SMA expression rate of all MLNs in the 
same patient (Pearson’s correlation coefficient: 0.859; 
Supplementary Figure 2A). A similar correlation was also 
observed for collagen (Pearson’s correlation coefficient: 
0.803; Supplementary Figure 2B). Therefore, we selected 
the largest MLN for analyses. Thus, it was not necessary 
to measure the α-SMA expression rate for all MLNs in 
clinical practice; hence, the data collection was more 
convenient. These results suggest that the degree of 
fibrosis of MLNs was not dependent on MLN diameter 
but by the nature of metastatic tumor.
collagen deposition in MLns in crc is 
associated with poor prognosis
Collagen deposition rate in the largest MLNs differed 
widely, ranging from 1.0% to 58.1% (Supplementary Figure 
3A) while the positive range of PTs was from 10.3% to 
43.2% (Supplementary Figure 3B). Collagen deposition 
was significantly higher in MLNs than in non-MLNs 
(MLN: 28.5 ± 15.0%; non-MLN: 2.1 ± 1.7%; P < 0.001). 
Similarly, collagen deposition rate at the invasive front of 
PTs was significantly higher than that in normal tissue (PT: 
20.9 ± 6.8%; normal tissue: 2.9 ± 1.3%; P < 0.001). A weak 
correlation occurred between collagen deposition rate of 
PTs and MLNs (Pearson’s correlation coefficient: 0.324). 
In Table 1, we showed the clinicopathological 
factors classified by high and low collagen deposition 
or α-SMA expression in MLNs. Significant differences 
occurred with higher collagen deposition (in MLN) 
in pathological tumor stage (p = 0.032), pathological 
node stage (p = 0.031), liver metastasis (p = 0.048), 
pathological stage (p = 0.013), and recurrence (p < 0.001). 
Higher collagen content (“High”) was indicative 
of higher recurrence rate (high: 58.6%; low: 13.6%; χ2 
test, p < 0.001; Table 1). As shown in Figure 2A, both 
relapse-free survival (RFS) and overall survival (OS) of 
the “High” collagen group were significantly shorter than 
those of the “Low” collagen group (RFS, log-rank p < 
0.001; OS, log-rank p = 0.001). As Figure 2B shows, the 
subgroup analysis of Stage III showed that the prognosis 
and the recurrence rate of the “High” group were 
significantly shorter than those of the “Low” group (RFS, 
log-rank p = 0.001; OS, log-rank p = 0.015). 
At the invasive front of PTs (all patients), high 
collagen deposition correlated with shorter RFS (log-rank 
p = 0.009) and OS (log-rank p = 0.002; Supplementary 
Figure 4A). Subgroup analysis showed that in Stage III 
patients, high collagen deposition of MLNs correlated 
with poor prognosis, but collagen deposition at the 
invasive front of the PTs did not significantly correlate 
with OS or RFS (Supplementary Figure 4B).
α-SMA expression of MLNs in CRC is related to 
rFs and os
We analyzed α-SMA expression in PTs and MLNs. 
The largest MLNs ranged from 13.5% to 49.6% positivity 
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(Supplementary Figure 3C) while the positive range of 
PTs was from 10.3% to 43.2% (Supplementary Figure 3D) 
for α-SMA expression. Similar to the collagen deposition, 
α-SMA expression was significantly higher in MLNs 
vs non-MLN (29.5 ± 8.6% vs 1.7 ± 1.9%, respectively; 
p < 0.001) and PTs vs normal tissue (26.6 ± 7.7 vs 1.2 ± 
1.1%, respectively; p < 0.001). There was no correlation 
between α-SMA expression rate of PTs and MLNs 
(Pearson’s correlation coefficient: 0.134). 
Clinicopathological factors were analyzed against 
α-SMA expression (Table 1), and revealed a positive 
correlation between α-SMA content and disease recurrence 
(high: 58.1%; low: 11.9%; χ2 test, p < 0.001). In addition, a 
higher α-SMA expression in the largest MLNs predicated 
lower RFS (log-rank p < 0.001) and OS (log-rank 
p = 0.001); Figure 3A. We conducted a subgroup analysis 
with Stage III patients and found a similar correlation of 
α-SMA expression with RFS (log-rank p < 0.001) and OS 
(log-rank p < 0.001); Figure 3B. 
At the invasive front of PTs (all patients), high 
α-SMA expression correlated with shorter OS, but not 
with RFS (Supplementary Figure 5A). Subgroup analysis 
showed that in Stage III patients, α-SMA expression at the 
invasive front of the PTs did not significantly correlate 
with OS or RFS (Supplementary Figure 5B). 
Univariate and multivariate Cox proportional 
hazards regression analyses to identify the 
prognostic factors associated with OS
CAFs produce transforming growth factor beta 
(TGF-β) and promote the expansion of extracellular matrix 
including type I collagen. In other words, both CAF and 
collagen are indicators of fibrosis, and their expression 
levels are expected to be correlated in cancer tissues. 
There was moderate positive correlation between α-SMA 
expression and collagen deposition rate in PTs (Pearson’s 
correlation coefficient: 0.521; Supplementary Figure 6A) 
and in MLNs (Pearson’s correlation coefficient: 0.603; 
Supplementary Figure 6B). Therefore, since the staining 
rates of α-SMA and collagen are confounding factors, 
these were analyzed separately.
Figure 1: H&E, Sirius Red, and α-SMA staining of (A) primary tumor and (b) metastatic lymph node. Sirius Red stains type I and 
III collagen in red. α-SMA is expressed in mesenchymal cells and stains brown upon immunohistochemistry. A field of view of 200× 
microscopic images (demarcated in red on the left) is shown on the right side, and was used for the statistical analysis. H&E, hematoxylin 
and eosin; α-SMA: α-smooth muscle actin.
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Table 1: Clinicopathological factors classified by collagen deposition and α-SMA expression in metastatic lymph 
nodes
Factors  N 
collagen
p-value 
α-SMA
p-valueHigh  
(N = 39) 
Low  
(N = 55)
High  
(N = 40)
Low  
(N = 54)
Age 94 66 (60–73) 66 (61–72) 0.854 66 (60–74) 66 (60–72) 0.643
Gender Male 59 25 34 0.498 25 34 0.566
Female 35 14 21 15 20
Preoperative 
CEA　
94 10.3 (5.8–32.8)
5.0 
(3.3–14.7) 0.025
* 8.6 
(3.9–19.5)
7.1 
(3.1–18.2) 0.479
Tumor site Right1) 28 8 20 0.076 10 18 0.260
Left2) 66 31 35 30 36 
Pathological 
tumor stage T2 11 1 10 0.032
* 4 7 0.313
T3 64 27 37 25 39 
T4 19 11 8 11 8
Pathological node 
stage N1 62 21 41 0.031
* 24 38 0.203
N2 32 18 14 16 16
Histological type Well3) 86 36 50 0.561 35 51 0.206
Poor4) 8 3 5 5 3 
Lymphatic 
permeation ly0,1 58 22 36  0.250 24 34  0.468
ly2,3 36 17 19 16 20
Vascular invasion v0,1 49 18 31 0.222 19 30 0.286
v2,3 45 21 24 21 24
Liver metastasis H(–) 72 26 46 0.048* 27 45 0.062
H(+) 22 13 9 13 9
Peritoneal 
dissemination P(–) 89 36 53 0.340 39 50 0.288
P(+) 5 3 2 1 4
Pathological 
Stage Stage III 66 22 44 0.013
* 25 41 0.119
Stage IV 28 17 11 15 13
Recurrence Liver 8 7 1 <0.001* 7 1 <0.001*
Lung 8 6 2 6 2
Local 
recurrence 7 4 3 5 2
No recurrence 50 12 38 13 37
Postoperative 
chemotherapy
With 
oxaliplatin
47 24 23 0.306 22 25 0.530
Without 
oxaliplatin
29 9 20 10 19
No 
chemotherapy 18 6 12 8 10
Associations between categorical variables were analyzed using either the χ2 test or the Fisher’s exact test. Age and preoperative CEA were 
analyzed using Mann–Whitney U test and expressed as the median value (interquartile range). 1) Right includes from cecum to transverse 
colon. 2) Left includes from descending colon to rectum below the peritoneal reflection. 3) Well includes 24 cases of well-differentiated 
adenocarcinoma and 62 cases of moderately differentiated adenocarcinoma. 4) Poor includes 4 cases of poorly differentiated adenocarcinoma, 
1 case of signet ring cell carcinoma and 3 cases of mucinous carcinoma. *Statistically significant. Abbreviations: α-SMA: α-smooth muscle 
actin; CEA: Carcinoembryonic antigen.
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We carried out univariate and multivariate Cox 
proportional hazards regression analyses to identify 
possible prognostic factors for OS in all patients 
(Table 2) and in Stage III patients (Table 3). Univariate 
Cox regression analysis showed that pathological tumor 
stage, pathological node stage, preoperative CEA, 
liver metastasis, peritoneal dissemination, and α-SMA 
expression in PTs and MLNs correlated significantly with 
OS. Multivariate Cox regression analysis showed that liver 
metastasis (HR, 1.80; 95% CI, 1.56–8.28; p = 0.005), 
peritoneal dissemination (HR, 1.96; 95% CI, 1.39–15.37; 
p = 0.033), and α-SMA expression in MLNs (HR, 
1.53; 95% CI, 1.03–4.94; p = 0.034) were independent 
prognostic factors for OS in all patients (Table 2). 
Expression rate of α-SMA in MLNs remained as a 
predictive factor for OS, when data from all patients as 
well as for Stage III patients were analyzed (HR, 3.01; 
95% CI, 1.54–6.60; p = 0.006; Table 3).
Then, we performed Cox regression analyses 
by adding collagen deposition as a factor instead of 
α-SMA expression. Collagen deposition in PTs and 
MLNs correlated significantly with OS in Stages III / IV 
Figure 2: Kaplan–Meier analyses of RFS and OS rates based on the collagen deposition rate of metastatic lymph nodes in (A) Stages III/
IV disease or (b) only Stage III disease. RFS: relapse-free survival; OS: overall survival. *Statistically significant.
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univariate analysis. However, collagen deposition rates of 
PTs and MLNs were not independent prognostic factors in 
multivariate analysis (Supplementary Table 1). Collagen 
deposition rates in PTs and MLNs were not prognostic 
predictors even in Stage III multivariate analysis 
(Supplementary Table 2).
On the other hand, higher α-SMA expression and 
collagen deposition in primary tumors were associated 
with short OS, but they were not significant factors in 
multivariate Cox regression analyses.
α-SMA positive stromal cells in MLN are 
fibroblastic reticular cells (FRCs) that co-express 
podoplanin (PdPn)
We performed IHC staining of stromal cells in 
MLNs with α-SMA, vimentin, and CD73 (a marker 
of mesenchymal cells). In order to confirm that the 
stromal cells are FRC, we performed immunostaining 
for positive markers: PDPN, platelet-derived growth 
factor receptor alpha (PDGFRA); and negative marker: 
Figure 3: Kaplan–Meier analyses of RFS and OS rate based on α-SMA expression rate of metastatic lymph nodes in (A) Stages III/ 
IV disease or (b) only Stage III disease. RFS: relapse-free survival; OS: overall survival; α-SMA: α-smooth muscle actin. *Statistically 
significant.
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CD31 (Figure 4A). We confirmed that α-SMA, PDPN, 
vimentin, PDGFRA, and CD73 were expressed in stromal 
cells of MLNs. On the other hand, CD31 stained vascular 
endothelial cells, but other stromal cells were not stained.
In 95% of patients (38/40 patients) with high 
MLN α-SMA expression, the stromal tissues of MLNs 
were stained positively for PDPN. Furthermore, the 
PDPN signal co-localized with α-SMA expression, 
which was further confirmed by IHC dual staining 
(Figure 4B); implying that the stromal cells in MLNs 
were FRCs.
dIscussIon
We demonstrated in this study that the high α-SMA 
expression in MLNs is a strong predictive factor for 
recurrence and survival rate among patients with advanced 
CRC. Our study demonstrates the clinical impact of 
fibrosis in MLNs on CRC. 
Neoplastic cells may stimulate tumor stromal 
fibroblasts via TGF-β pathway to cause tissue fibrosis 
and matrix production [12, 19, 20], resulting in a 
desmoplastic reaction (DR). Recent clinical reports 
hypothesize that stromal fibrosis of PTs promotes 
invasion and metastasis in CRC, and that DR contributes 
to poor prognosis [21, 22]. Tsujino [13] reported that the 
abundance of tumor myofibroblasts predicted shorter 
disease-free survival in Stages II and III CRC. Halvorsen 
[14] reported that pronounced fibrosis at the tumor edge 
correlates with unfavorable stage distributions, while 
Herrera [15] reported that the presence of tumor CAFs 
dictates clinical outcome in CRC patients, implying that 
fibrosis in the PT accelerates tumor progression. As in 
these reports, we investigated α-SMA expression in both 
the central part and the invasive front of PTs and revealed 
that stromal fibrosis at the invasive front, not the central 
part, of PTs was correlated with poor prognosis (data 
not shown). We speculated that the difference in clinical 
meaning between tumor invasive front and tumor central 
occurred because of the hypoxic condition and high 
interstitial pressure. These severe conditions might cause 
apoptosis of fibroblasts and change in fibrotic condition 
in the central part of the PT. We suggested that this 
difference in the microenvironment caused the fibrotic 
Table 2: Univariate and multivariate Cox proportional hazards regression analyses of clinicopathological factors 
including α-SMA expression rate in primary tumors and metastatic lymph nodes for overall survival in Stage III/
IV colorectal cancer patients
Factors
univariate Multivariate
Hr 95% cI p-value Hr 95% cI p-value
Pathological tumor stage T2,3/T4 3.55 1.72–7.29 0.001* 1.45 0.18–11.39 0.391
Pathological node stage N1/N2 1.65 1.17–2.34 0.005* 1.34 0.77–3.50 0.145
Preoperative CEA ≦5/>5 1.95 1.21–3.14 0.006* 1.37 0.85–10.44 0.233
Liver metastasis H–/H+ 2.26 1.60–3.20 <0.001* 1.80 1.56–8.28 0.005*
Peritoneal dissemination P–/P+ 1.94 1.14–3.29 0.015* 1.96 1.39–15.37 0.033*
α-SMA in primary tumors Low/High 1.56 1.04–2.33 0.030* 1.18 0.56–3.55 0.463
α-SMA in metastatic lymph nodes Low/High 1.80 1.25–2.59 0.002* 1.53 1.03–4.94 0.034*
*Statistically significant. Abbreviations: α-SMA: α-smooth muscle actin; CEA: Carcinoembryonic antigen; HR: hazard 
ratio; CI: confidence interval.
Table 3: Univariate and multivariate Cox proportional hazards regression analyses of clinicopathological factors 
including α-SMA expression rate in primary tumors and metastatic lymph nodes for overall survival in only Stage 
III colorectal cancer patients
Factors 
univariate Multivariate
Hr 95% cI p-value Hr 95% cI p-value
Pathological tumor stage T2,3/T4 3.20 0.85–12.11 0.086  1.21 0.23–6.34 0.824
Pathological node stage N1/N2 1.84 1.01–3.33 0.045* 1.54 0.76–3.12 0.233
Preoperative CEA ≦5/>5 1.33 0.72–2.46 0.360 1.27 0.67–2.39 0.467
α-SMA in primary tumors Low/High 1.10 0.61–2.00 0.747 1.17 0.64–2.15 0.608
α-SMA in metastatic lymph nodes Low/High 3.17 1.47–6.85 0.003* 3.01 1.54–6.60 0.006*
*Statistically significant. Abbreviations: α-SMA: α-smooth muscle actin; CEA: Carcinoembryonic antigen; HR: hazard ratio; 
CI: confidence interval.
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status. It is known that cancer cells at the invasive front 
of PT stimulate TGF-β production and increases the 
extracellular matrix, including collagen [23], resulting 
in the induction of epithelial-mesenchymal transition 
followed by the promotion of tumor invasion and 
metastasis [24]. In contrast to the above, Özdemir et al. 
[16] showed that the suppression of SR or removal of 
fibroblasts around the PTs in mice pancreatic cancer 
correlated with shorter survival. Thus, the effect of peri-
tumoral stromal response on tumor progression is still 
controversial. 
Several multicenter prospective CRC studies 
revealed that only the pathological stage (specified as 
pathological tumor stage, pathological node stage, and 
distant metastasis) was a reliable prognostic factor [25, 
26]. In addition, intestinal perforation or obstruction, 
residual cancer cells in the surgical margin, lymphatic 
permeation, perineural invasion, poorly differentiated 
histology, and high preoperative CEA level also signify 
worse prognosis [27–29]. Consistent with the above, 
we showed that pathological tumor stage, pathological 
node stage, liver metastasis, peritoneal dissemination, 
and preoperative CEA in univariate analysis, and liver 
metastasis and peritoneal dissemination in multivariate 
analysis, significantly influenced disease prognosis. 
Surprisingly, the fibrosis of the largest MLNs reflected 
poor prognosis strongly same as the above factors, 
implying that fibrosis in MLNs may be a promising 
biomarker.
The tumor microenvironment hosts diverse 
cell types, including immune cells, fibroblasts, and 
endothelial cells, which dynamically remodel tumor tissue 
[12, 30, 31]. Fibroblasts, localized in tumor stromal tissue 
(CAFs) express α-SMA [12, 32, 33], which is an actin 6 
isoform, important for contractile function [34]. Tissue 
fibrosis facilitates cell-to-cell interactions, which play a 
major role in carcinogenesis [35–37]. Initial host-tumor 
interactions activate wound-repair mechanisms and scar-
tissue formation around the tumor. However, subsequently, 
malignant cells facilitate growth factor release, leading to 
neovascularization and tumor invasion. One hypothesis 
states that the dense collagen secreted by myofibroblasts 
represents an attempt to defend the host by containing 
the tumor and delaying vascularization [38]. CAFs may 
originate from resident fibroblasts, mesenchymal stem 
cells, fibrocytes, or transformed endothelial cells by 
epithelial-mesenchymal transition [39]. 
Tumor metastasis is a factor of poor prognosis. In 
this study, the multivariate Cox analysis also revealed that 
liver metastasis was a crucial poor prognosis. The aim of 
this study was to demonstrate whether or not angiogenesis 
or lymphangiogenesis, which facilitates tumor metastasis 
at the invasive front of PT, is associated with stromal 
fibrosis. Therefore, for the PT, we stained CD31, the 
Figure 4: (A) Immunohistochemistry for α-SMA, PDPN, vimentin, PDGFRA, CD73, and CD31 in metastatic lymph node (400×). 
α-SMA, PDPN, vimentin, PDGFRA, and CD73 stained stromal cells in metastatic lymph node. CD31 was not stained in stromal cells. 
(b) Immunofluorescence images of the stroma of a metastatic lymph node (400×), stained for α-SMA (green), PDPN (red), and DAPI 
(blue). Dual staining for PDPN and α-SMA confirms the co-expression of the two proteins in the FRCs of metastatic lymph node. α-SMA: 
α-smooth muscle actin; PDPN: podoplanin; PDGFRA: platelet-derived growth factor receptor α; DAPI: 4’,6-Diamidino-2-phenylindole; 
FRCs: fibroblastic reticular cells.
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marker for blood vessels, and PDPN, the marker for 
lymphatic vessels, and investigated correlations between 
the expression rates of these markers at the invasive 
front of PT and those of α-SMA and collagen (Pearson’s 
correlation coefficient: CD31 and α-SMA, 0.109; 
PDPN and α-SMA, 0.168). According to our findings, 
associations between these factors appeared weak. It is 
also possible that fibrosis which induces tumor growth and 
metastasis, are the secondary effects of increased tumor 
growth. Fibrotic change may also physically facilitate 
the migration of tumor cells. In addition, we also stained 
Ki67 to investigate the relationship between fibrosis in the 
tumor and tumor cell proliferation (data not shown). There 
was no correlation between expression of Ki67 and those 
of α-SMA and collagen (Pearson’s correlation coefficient: 
Ki67 and α-SMA, 0.028). Thus, no correlation was shown 
between tumor metastasis stimulating factors, such as 
angiogenesis, lymphangiogenesis and tumor cell growth in 
PT; and fibrosis of tumor-associated stroma. This suggests 
that fibrotic change is not facilitated by the secondary 
effect of the tumor metastasis stimulating factors.
From past study, it is known that the stromal 
fibroblastic cells in LNs are FRCs. In the paracortical 
areas of the LNs, FRCs are the structural skeleton of 
the LN and express PDPN, producing collagen III 
rich reticular fibers that form a dense network within 
the lymphoid tissue [40]. FRCs are immunologically 
specialized myofibroblasts of mesenchymal origin. They 
can be differentiated from other lymph node-resident cells 
by the expression of PDPN and PDGFRA, and the lack of 
expression of CD31 and CD45. FRCs express molecules 
common to many myofibroblasts, including α-SMA, 
vimentin, desmin, CD90, CD73, CD103, and the ERTR7 
antigen [41]. PDPN is known to increase the migratory 
ability of dendritic cells and induce angiogenesis 
by acting on platelets in the medulla of LNs. FRCs 
recognize bacteria, viruses, and other microorganisms; 
thus preventing infection [42–47]. Here, we show that 
the stroma of MLNs contains α-SMA positive cells with 
PDPN expression, suggesting that the mesenchymal cells 
in MLNs may be FRCs. Though Yeung et al. [48] reported 
the presence of myofibroblasts in MLNs of CRC patients, 
we proved for the first time that a part of myofibroblasts 
in MLN are FRCs. 
It is novel to determine whether or not fibrotic 
change in metastatic lymph nodes, as a marker, can 
determine whether a patient should receive either 
adjuvant chemotherapy or any other drug. According to 
the results of our study, no difference was observed in OS 
and RFS regardless of whether the patient had received 
either adjuvant chemotherapy or oxaliplatin (out of all 
chemotherapy drugs), or not; both in all patients and in 
Stage III patients. We also categorized the patients into 
two (severe or mild fibrosis groups), and then investigated 
their survival rates with or without adjuvant chemotherapy. 
However, there was no significant difference observed 
between the two groups (data not shown). The subjects in 
this study were in Stages III or IV. More than 80% of the 
patients received adjuvant chemotherapy while patients 
in poor general condition or the elderly had not received 
chemotherapy; suggesting that the patients’ background, 
whether or not they had received chemotherapy varied 
greatly. Therefore, there is a limitation in this retrospective 
study. For further investigation, a prospective cohort study 
is suggested with a larger sample size.
In summary, we show that fibrosis in MLNs is 
a strong prognosticator of poor OS and RFS in CRC 
patients. Malignant cells with high metastatic potential 
may be prone to causing fibrotic reactions and collagen 
deposition in LNs. We also showed that patients with 
fibrotic LN metastases are at high risk of recurrence and 
shorter survival rate. Intensive follow up is therefore 
recommended in such patients.
The primary limitation of this study is its 
retrospective, single-center nature. In addition, the sample 
size was small, and the role of FRCs was not clarified. To 
further understand the clinical implications of metastatic 
fibrotic LNs in CRC patients, a prospective study with a 
larger sample size and long-term follow-up is required. 
Under the present circumstances, the role of α-SMA 
expressing FRC in MLNs was not clarified. By elucidating 
its mechanism, the therapeutic benefit of the influence of 
stromal response can be assessed.
MAtErIALs And MEtHods
Patients and samples
We reviewed a total of 104 consecutive colorectal 
adenocarcinoma patients with LN metastasis who 
underwent colectomy between January 2010 and 
December 2013 at Shiga University of Medical Science 
Hospital (Shiga, Japan). We excluded three patients 
who had other carcinomas (i.e., liver, lungs, or ovaries) 
and seven, who received oxaliplatin-based preoperative 
chemotherapy from the analyses. Finally, a total of 94 
patients were included in the analysis. The tissue samples 
included 66 Stage III and 28 Stage IV carcinomas; graded 
according to the Union for International Cancer Control 
(UICC) tumor-node-metastasis (TNM) classification 
of malignant tumors, 7th edition [49]. Based on the 
Japanese Society for Cancer of Colon and Rectum 
(JSCCR) guidelines [50], the majority of patients (76 
[80.9%]) received 5-fluorouracil-based postoperative 
chemotherapy (47 of 76 patients received oxaliplatin-
added chemotherapy while the remaining 29, received 
oxaliplatin-free chemotherapy). The follow-up protocol in 
CRC survivors involved physical examination and tumor 
marker tests, every three months, as well as CT scan, every 
six months. Tumor samples were classified into “High” and 
“Low” staining rate groups. This research was approved by 
the Human Ethics Review Committee of Shiga University 
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of Medical Science. We published an opt-out option on the 
Website of Shiga University of Medical Science; hence, 
the requirement for written informed consent was waived.
H&E staining and IHc
Tissue sections (4 µm thick) were prepared from 
10% formalin-fixed paraffin-embedded blocks and stained 
with H&E. For IHC, slides were deparaffinized by xylene 
treatment and rehydrated by passing them through an 
ethanol gradient, and then heated in an electric kettle with 
antigen retrieval solution (Immunosaver®, Nisshin EM, 
Tokyo, Japan). Endogenous peroxidases were inactivated 
in a methanolic 3% hydrogen peroxide solution for 
10 minutes, and subsequently incubated with a blocking 
reagent (Blocking One®, Nacalai Tesque, Kyoto, Japan) for 
20 minutes. The tissue sections were incubated overnight 
at 4°C with an anti-α-SMA antibody (1:100, ab7817, 
Abcam, Cambridge, UK), anti-PDPN antibody D2-40 (code 
413451, NICHIREI BIOSCIENCES INC., Tokyo, Japan), 
anti-vimentin antibody (1:100, M7020, Dako, Carpinteria, 
USA), anti-fibronectin antibody (1:100, ab2413, Abcam), 
anti-FAP antibody (1:100, ab28244, Abcam), anti-PDGFRA 
antibody (1:200, #5241, Cell Signaling Technology, Inc., 
Danvers, USA), anti-CD73 antibody (1:100, ab133582, 
Abcam), anti-CD31 antibody (1:50, ab124432, Abcam), or 
anti-Ki67 antibody (1:100, ab16667, Abcam). The following 
day, the slides were incubated with a secondary antibody 
(Simple Stain MAX PO®, NICHIREI BIOSCIENCES 
INC.) for 30 minutes, and the antigen was visualized by 
diaminobenzine staining (DAB®, DAKO) for 10 minutes.
collagen staining
Collagen (type I and type III) was stained with 
Picro-Sirius Red, using the Elastica van Gieson staining 
kit (MUTO PURE CHEMICALS, Tokyo, Japan). Tissue 
sections (4 µm thick) were incubated for 1 hour with 
a resorcin-fuchsin solution and further incubated for 
5 minutes with Weigert’s iron hematoxylin solution. A 
final incubation was performed with 1% Sirius Red and 
van Gieson’s stain for 10 minutes. Collagen (type I and 
type III) was stained red by Sirius Red.
Dual immunofluorescence staining
Tissue sections (2 µm thick) were processed using 
the IHC protocol as above. PDPN was detected with 
anti-PDPN antibody (1:200, bs-17742R, Bioss Inc., 
Massachusetts, USA), and α-SMA with an anti-α-SMA 
antibody (1:100, ab7817, Abcam). Secondary antibodies 
employed were Alexa Fluor 488 goat anti-mouse 
(A-11029), or Alexa 594 goat anti-rabbit (A-11012) 
(Molecular Probes, Invitrogen, Carlsbad, USA), at a 
dilution of 1:200. Tissues were incubated with secondary 
antibodies for 60 minutes. ProLong® Diamond Antifade 
Mountant with 4’,6-diamidino-2-phenylindole (P36962, 
Molecular probes, Invitrogen) was used as the mounting 
agent. A Fluoview FV1000-D microscope (Olympus, 
Tokyo, Japan) was used for image analysis.
IHc and collagen scoring
Blinded microscopic evaluation of the slides 
was performed by an experienced pathologist (K.M.). 
The pathologist, in consultation with the author (D.I.), 
demarcated five areas at a magnification of 200× for 
analyses, and the average staining rate of stromal 
cells excluding tumor cells was quantitated by Image J 
(National Institutes of Health, Bethesda, USA).
We examined the largest cross-sectional slice in 
PTs, emphasizing the invasive front (features here reflect 
tumor metastatic potential) [24, 25]. The muscle layer was 
excluded from the assessment, since the muscle fibers are 
known to express α-SMA. We used the staining rate of the 
largest diameter MLNs for the analyses of survival rate. The 
expression of α-SMA and Collagen in non-MLN stroma 
was very few and there was no difference in their expression 
between non-MLNs of a single patient. Therefore, we used 
the largest diameter non-MLN for analysis.
statistical analysis
Statistical analysis was performed using the 
Statistical Package for the Social Sciences software 
(SPSS, version 22.0, IBM, Armonk, New York, USA). 
RFS was the time from curative surgery to the time of 
first tumor recurrence or the final follow-up date while 
OS was the time from colorectal cancer resection to the 
time of all-cause mortality or the final follow-up date. 
Survival analysis was by the Kaplan–Meier method, and 
the comparison of survival time between subgroups was 
by log-rank test. Multivariate analysis was performed 
using the Cox proportional hazards regression model. 
Associations between categorical variables were analyzed 
using either the χ2 test or the Fisher’s exact test. We 
correlated the data based on the tumor categories with 
the clinicopathological factors. The staining rates of 
α-SMA and collagen in all specimens followed the 
normal distribution by Kolmogorov-Smirnov test. 
Mean values were reported from the Student’s t-test and 
expressed as the mean value ± SD when data followed 
a normal distribution. We used the Mann–Whitney U 
test to compare factors (age and preoperative CEA) 
that did not follow the normal distribution. The receiver 
operating characteristic (ROC) curve analyses based on 
the 48-month OS of all patients (Supplementary Figure 
7A–7D) was performed; while the maximum value of 
the Youden’s Index (Sensitivity + Specificity – 1) was 
determined as the cut-off value of α-SMA expression and 
the collagen deposition rate. We determined the “High” 
and “Low” staining rate groups as cases with higher and 
Oncotarget29584www.oncotarget.com
lower staining rates, respectively, compared to the cut-off 
value. The same cut-off value used for analyses of OS in 
all patients was also used for RFS and Stage III patients’ 
analyses. The significance level was set at p < 0.05.
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